Mark Baldry - 03 Nov 2022 Form 4 Insider Report for X4 Pharmaceuticals, Inc (XFOR)

Reporting relationship: Chief Commercial Officer
Issuer ticker: XFOR
Reported as of: 03 Nov 2022
Net transaction value: +$644,490
SEC form: 4
Accepted by SEC: 04 Nov 2022, 16:18:11 UTC
Next SEC filing: 02 Nov 2023
Source filing: View source filing
Reporting owner signature: /s/ Adam S. Mostafa, attorney-in-fact

Key filing fact

Mark Baldry filed Form 4 for X4 Pharmaceuticals, Inc (XFOR) on 04 Nov 2022.

Key facts

This page summarizes Mark Baldry's Form 4 filing for X4 Pharmaceuticals, Inc (XFOR).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 Nov 2022, 16:18.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: +$644,490.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

XFOR transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $644,490
Shares: +341,000
Change %
Price: $1.89
Shares after: 341,000
Date: 03 Nov 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 341,000
Exercise price: $1.89
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

25% of the shares subject to the option shall vest on November 3, 2023, with the remainder vesting in equal installments of 2.0833% of the shares subject to the option each successive month thereafter for a period of 36 months, subject to the Reporting Person continuing to provide services through each such date.